ISPOR Europe 2018
Barcelona, Spain
November, 2018
PHP315
Multiple Diseases/No Specific Disease
Health Care Use & Policy Studies (HP)
Health Technology Assessment Programs (HTA)
HOW FREQUENTLY IS PATIENT EXPERIENCE FORMALLY ASSESSED IN HEALTH TECHNOLOGY ASSESSMENTS? RESULTS FROM A SYSTEMATIC LITERATURE REVIEW
Sarri G1, Kenny J1, Freitag A1, Mountian I2, Szegvari B2, Brixner D3, Maniadakis N4
1Evidera, London, UK, 2UCB Pharma, Brussels, Belgium, 3University of Utah, Salt Lake City, UT, USA, 4National School of Public Health, Athens, Greece
OBJECTIVES

:
Patient experience (PEx) is an integral aspect of patient-centered care and increasingly recognized as an important focus area in health technology assessments (HTAs). PEx is a multifactorial concept encompassing interactions with health care systems and treatment expectations. This study aimed to determine whether and how frequently PEx and patient support services (PSS) were considered by manufacturers and HTA decision-makers.

METHODS

:
A systematic literature review of 12 HTA bodies was undertaken in October 2017 to identify HTA submissions and decisions (published in English since 1 January 2012) considering patient support services (PSS) and factors relating to PEx. Seven chronic diseases were selected due to high disease burden: diabetes, rheumatoid arthritis, axial spondyloarthritis, ankylosing spondylitis, psoriasis, systemic lupus erythematosus, Parkinson’s disease, and epilepsy.

RESULTS

:
English documents were available for Australian, Canadian, French, German, US, and two UK HTA bodies. Of the 168 HTA submissions reviewed, 122 (73%) received a positive HTA recommendation. Less than half of company submissions were available in full (42%), whereas the majority of HTA assessments were accessible (81%). Considerations relating to PSS were included in 1% (2/168) of company submissions (both submissions related to route of administration) and factors relating to PEx (route of administration, disease burden, and impact on carers) were discussed in 11% (19/168) of HTA submissions. No detailed discussion of how PEx was incorporated during decision-making was identified. A supplementary review of NICE clinical guidelines for the same chronic diseases revealed that PSS recommendations were included in the disease pathway in 3 out of 7 guidelines.

CONCLUSIONS

:
PEx and the role of PSS were rarely considered by manufacturers or HTA decision makers. Due to the lack of clear HTA methodology regarding the formal consideration of PEx in decision-making, the increasing real-world effectiveness of therapeutic solutions may not be fully recognized. Further HTA guidance on this topic is needed.